Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
April 25, 2023 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative Medicines (IM)...
Novartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023
April 25, 2023 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Au T1, chiffre d’affaires en hausse de +8% (tcc1, +3% USD) et du résultat opérationnel de +15% (tcc, +8% USD) Innovative Medicines (IM): hausse de...
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
April 20, 2023 01:15 ET
|
Novartis Pharma AG
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of...
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
March 31, 2023 07:53 ET
|
Novartis Pharma AG
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric...
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
March 27, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is...
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
March 16, 2023 18:47 ET
|
Novartis Pharma AG
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigen die 26. Dividendenerhöhung in Folge auf CHF 3,20 (+3,2 %) pro Aktie für 2022; dies entspricht einer Rendite von 4.0 %1 und einer Ausschüttung von rund 61 %...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Les actionnaires approuvent la 26e augmentation consécutive du dividende à CHF 3,20 (+3,2%) par action pour 2022 ; représentant un rendement de 4.0%1 et une distribution du free cash-flow d’environ...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Shareholders approve 26th consecutive dividend increase to CHF 3.20 (+3.2%) per share for 2022; representing a 4.0% yield1 and approximately 61% payout of free cash flow Shareholders confirm Joerg...
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
February 03, 2023 18:30 ET
|
Novartis Pharma AG
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16...